You will be shown the abstract of a medical clinical trial report. Your task is to extract all the findings from this report into a JSON array. Each finding should contain the following five elements:

- Intervention: The medical intervention being tested. This should be a text span copied from the input passage.
- Comparator: The baseline against which the intervention is being evaluated. This should be a text span copied from the input passage. If no comparator is reported, set to `null`.
- Outcome: The medical outcome whose effect is being measured. This should be a text span copied from the input passage.
- Effect: The effect of the intervention on the outcome, relative to the comparator. The effect should be one of the following three values: ("significantly increased", "significantly decreased", "no significant difference").
- Evidence: The evidence for the effect. This should be a text span copied from the input passage.

Please format your output as a JSON array. Each entry in the output should be an array containing the 5 elements listed above, in the following order: [<intervention>, <comparator>, <outcome>, <effect>, <evidence>].

For example, an output with two findings might read:
```
[["aspirin", "placebo", "headache severity", "significantly decreased", "Mean headache severity was significantly decreased in the aspirin group compared to the placebo group (p < 0.05)."], ["aspirin", "placebo", "weight loss", "no significant difference", "We did not observe any difference in weight loss between the group given aspirin relative to the control group"]]
```

There are 2 finding(s) in the abstract below. Please extract them. Output only the JSON array with these 2 findings. Do not include any additional text.

Abstract:
ABSTRACT: Objective: To assess clinically relevant symptom improvement in patients with major depressive disorder (MDD) receiving vilazodone by using the Montgomery-Asberg Depression Rating Scale (MADRS), a clinician-rated scale used to measure MDD symptom severity and improvement. <p> Method: Pooled data from 2 positive, phase 3, 8-week, double-blind, randomized, placebo-controlled trials in patients with MDD were analyzed. Patients received vilazodone 40 mg/d or placebo; post hoc analyses were conducted on study completers. Depression symptom improvement was evaluated by analyzing the proportions of patients who shifted from the baseline MADRS single-item symptom severity category of ≥ 2 (mild to severe symptoms) to an end-of-study category < 2 (minimal to no symptoms) or from ≥ 4 (moderate to severe symptoms) to ≤ 2 (mild to no symptoms). The proportion of patients who shifted from anxious depression to no anxious depression was also analyzed. <p> Results: The percentage of patients who completed these studies with severity category shift from baseline ≥ 2 to end of study < 2 was significantly higher for vilazodone versus placebo on all MADRS items (odds ratio [OR] range, 1.4–1.7, P < .05) except reduced appetite (OR = 1.3, P = .232). A significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from baseline ≥ 4 to end of study ≤ 2 on MADRS items of apparent sadness, reported sadness, inner tension, reduced sleep, and lassitude (OR range, 1.5–2.0, P < .05). Additionally, a significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from anxious depression at baseline to no anxious depression at end of study (OR = 1.5, P = .031). <p> Conclusions: These results suggest that vilazodone treatment is associated with clinically relevant changes in depression symptoms in patients with MDD. <p> Trial Registration: ClinicalTrials.gov identifiers: NCT00285376 and NCT00683592

Findings:
[["Vilazodone", "Placebo", "Overall severity category shift from \u2265 4 to \u2264 2 ", "significantly increased", "A significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from baseline \u2265 4 to end of study \u2264 2 on MADRS items of apparent sadness, reported sadness, inner tension, reduced sleep, and lassitude (OR range, 1.5\u20132.0, P \u003c .05)."], ["Vilazodone", "Placebo", "Abscense of anxious depression", "significantly increased", "a significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from anxious depression at baseline to no anxious depression at end of study (OR = 1.5, P = .031)."]]